www.neurologiepropraxi.cz / Neurol. praxi. 2025;26(4):345-349 / NEUROLOGIE PRO PRAXI 349 SDĚLENÍ Z PRAXE Hereditární spastická paraparéza typu 6 (SPG6) s fenotypickou konverzí do ALS LITERATURA 1. Amador MD, Muratet F, Teyssou E, et al. Spastic paraplegia due to recessive or dominant mutations in ERLIN2 can convert to ALS. Neurol Genet. 2019;5(6):e374. doi:10.1212/ NXG.0000000000000374. 2. Arkadir D, Noreau A, Goldman JS, et al. Pure hereditary spastic paraplegia due to a de novo mutation in the NIPA1 gene. Epilepsia. 2014;55(4):e36–e39. doi:10.1111/ene.12284. 3. Bürger JM, Hazan J, Martin JJ. Hereditární spastické paraplegie: Genetická heterogenita a fenotypové projevy. J Neurol. 2000;247(Suppl 5):34-42. 4. Du J, Hu Y, Tang B, et al. Expansion of the phenotypic spectrum of SPG6 caused by mutation in NIPA1. Clin Neurol Neurosurgery. 2011;113(6):480-482. doi:10.1016/j.clineuro.2011.02.011. 5. Fink J, Klobusiakova P, Balazova Z, et al. Hereditäre spastische Paraplegien. Nervenarzt. 2003;74(6):497-504. doi:10.1007/ s00115-003-1516-3. 6. Fu J, Ma M, Li G, et al. Clinical and Genetic Features of Chinese Patients With NIPA1-Related Hereditary Spastic Paraplegia Type 6. Front Genet. 2022;13:859688. doi:10.3389/fgene.2022.859688. 7. Fullam T, Statland J. Upper motor neuron disorders: primary lateral sclerosis, upper motor neuron dominant amyotrophic lateral sclerosis, and hereditary spastic paraplegia. Brain Sci. 2021;11(6):611. doi:10.3390/brainsci11060611. 8. Goytain A, Hines RM, El-Husseini A, et al. NIPA1 (SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional Mg2+ transporter. J Biol Chem. 2007;282(11):8060-8068. doi:10.1074/jbc. M610314200. 9. Harding AE, Klobusiakova P, Balazova Z, et al. Classification of the hereditary ataxias and paraplegias. Lancet. 1983;1(8334):1151-1155. 10. Hart CG, Karimi-Abdolrezaee S, Klobusiakova P, et al. Bone morphogenetic proteins: New insights into their roles and mechanisms in CNS development, pathology and repair. Exp Neurol. 2020;334:113455. doi:10.1016/j.expneurol.2020.113455. 11. Klebe S, Lacour A, Durr A, et al. NIPA1 (SPG6) mutations are a rare cause of autosomal dominant spastic paraplegia in Europe. Neurogenetics. 2007;8:155-157. doi:10.1007/s10048-006-0074-9. 12. Kume K, Kamada M, Shimatani Y, et al. Novel monoallelic variant in ERLIN2 causes spastic paraplegia converted to amyotrophic lateral sclerosis. J Neurol Sci. 2021;430:119984. doi:10.1016/j.jns.2021.119984. 13. Martinez-Lage M, Molina-Porcel L, Falcone D, et al. TDP43 Pathology in a Case of Hereditary Spastic Paraplegia with a NIPA1/SPG6 Mutation. Acta Neuropathol. 2012;124(3):285– 291. doi:10.1007/s00401-012-0947-y. 14. Radziwonik-Frączyk W, Elert-Dobkowska E, Kubalska J, et al. Co-occurrence of CAPN3 homozygous mutation and CCTG expansion in the CNBP gene in a patient with muscular dystrophy. Adv Psychiatry Neurol. 2024;33(2):109–114. doi:10.5114/ppn.2024.141382. 15. Ruano L, Melo C, Silva MC, et al. The global epidemiology of hereditary ataxia and spastic paraplegia: A systematic review of prevalence studies. Neuroepidemiology. 2014;42:174-183. 16. Schymick J, Talbot K, Traynor B. Genetics of sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2007;16(Suppl 2):R233-R242. doi:10.1093/HMG/DDM215. 17. Tanti M, Cairns D, Mirza N, et al. Is NIPA1-associated hereditary spastic paraplegia always ‘pure’? Further evidence of motor neurone disease and epilepsy as rare manifestations. Neurogenetics. 2020;21:305–308. doi:10.1007/ s10048-020-00619-0. 18. Teyssou E, Chartier L, Amador MD, et al. Novel UBQLN2 mutations linked to amyotrophic lateral sclerosis and atypical hereditary spastic paraplegia phenotype through defective HSP70-mediated proteolysis. Neurobiol Aging. 2017;58:239.e11239.e20. doi:10.1016/j.neurobiolaging.2017.06.018. 19. Theuriet J, Pegat A, Leblanc P, et al. Phenoconversion from spastic paraplegia to ALS/FTD associated with CYP7B1 compound heterozygous mutations. Genes (Basel). 2021;12(12):1876. doi:10.3390/genes12121876. 20. Tsang HT, Edwards TL, Wang X, et al. The hereditary spastic paraplegia proteins NIPA1, spastin, and spartin are inhibitors of mammalian BMP signalling. Hum Mol Genet. 2009;18(20):3805-3821. doi:10.1093/hmg/ddp324. 21. Uhrová Mészárosová A, Mazanec R, Seeman P. Hereditární spastické paraparézy: klinické a genetické aspekty. Neurol. praxi. 2016;17(6):373-376. 22. Zhao J, Matthies DS, Botzolakis EJ, et al. Hereditary spastic paraplegia-associated mutations in the NIPA1 gene and its Caenorhabditis elegans homolog trigger neural degeneration in vitro and in vivo through a gain-of-function mechanism. J Neurosci. 2008;28(51):13938-13951. doi:10.1523/JNEUROSCI.4668-08.2008. 23. Zumrová A, Mazanec R, Vyhnálek M, et al. Concomitancy of mutation in FRDA gene and FMR1 premutation in 58-year- -old woman. Neuro Endocrinol Lett. 2005;26(1):71-74. 11. 12. 6. 2026 BRNO 23. sympozium praktické neurologie MÍSTO KONÁNÍ: Hotel International Brno Husova 200/16, 602 00 Brno
RkJQdWJsaXNoZXIy NDA4Mjc=